Shares of Regulus Therapeutics Inc. (RGLS) are soaring over 60 percent on Tuesday morning following the announcement of positive data from the company's Phase 1b MAD trial of of RGLS8429 along with private placement of $100 million.
The trial results showed that RGLS8429 was well-tolerated with no safety concerns in the patients with Autosomal Dominant Polycystic Kidney Disease or ADPKD.
Also, the investors had agreed to purchase the company's shares at $1.60 per share, and a new class of non-voting Class A-6 convertible preferred stock at $160.00 per share under the private placement.
Currently, Regulus's stock is trading at $2.22, up 60.14 percent over the previous close of $1.38 on the volume of around 82 million on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.